(Updated - July 1, 2020 7:22 AM EDT)

(updating comment)Needham & Company analyst Serge Belanger downgraded Zynerba Pharmaceuticals (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades Hot Comments Hot Downgrades

Zynerba Pharmaceuticals (ZYNE) PT Lowered to $12 at Canaccord GenuityJuly 1, 2020 7:04 AM Increasing unusual option volume: WKHS ZYNE HIMX BGCP INVH MT ELFJuly 1, 2020 4:28 AM Zynerba Pharmaceuticals (ZYNE) PT Lowered to $8.50 at Roth Capital, After Study Misses EndpointsJune 30, 2020 2:15 PM Pre-Open Movers 06/30: (CARV) (BYFC) (BLNK) Higher; (OCX) (ZYNE) (GNW) Lower (more...)June 30, 2020 9:27 AM Form 8-K Zynerba Pharmaceuticals, For: Jun 30June 30, 2020 6:59 AM Zynerba Pharma (ZYNE) Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome Did Not Achieve Statistical SignificanceJune 30, 2020 6:47 AM Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X SyndromeJune 30, 2020 6:46 AM Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X SyndromeJune 30, 2020 6:45 AM